Cargando…

Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-analysis

IMPORTANCE: Widely available and affordable options for the outpatient management of COVID-19 are needed, particularly for therapies that prevent hospitalization. OBJECTIVE: To perform a meta-analysis of the available randomized clinical trial evidence for fluvoxamine in the outpatient management of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Todd C., Vigod, Simone, Bortolussi-Courval, Émilie, Hanula, Ryan, Boulware, David R., Lenze, Eric J., Reiersen, Angela M., McDonald, Emily G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987902/ https://www.ncbi.nlm.nih.gov/pubmed/35385087 http://dx.doi.org/10.1001/jamanetworkopen.2022.6269

Ejemplares similares

Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-analysis
por: Hanula, Ryan, et al.
Publicado: (2023)

Inhaled corticosteroids for outpatients with COVID-19: a meta-analysis
por: Lee, Todd C., et al.
Publicado: (2022)

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence
por: Facente, Shelley N., et al.
Publicado: (2021)

Drug Interactions With Nirmatrelvir-Ritonavir in Older Adults Using Multiple Medications
por: Ross, Sydney B., et al.
Publicado: (2022)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
por: Reiersen, Angela M, et al.
Publicado: (2023)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Electronic Decision Support for Deprescribing in Patients on Hemodialysis: Clinical Research Protocol for a Prospective, Controlled, Quality Improvement Study
por: Bortolussi-Courval, Émilie, et al.
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Deprescribing Opportunities for Hospitalized Patients With End-Stage Kidney Disease on Hemodialysis: A Secondary Analysis of the MedSafer Cluster Randomized Controlled Trial
por: Moryousef, Joseph, et al.
Publicado: (2022)

Spread and scale of an electronic deprescribing software to improve health outcomes of older adults living in nursing homes: study protocol for a stepped wedge cluster randomized trial
por: Nadeau, Marc-Eric, et al.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
por: Sukhatme, Vikas P., et al.
Publicado: (2021)

Association between antidepressant use and ED or hospital visits in outpatients with SARS-CoV-2
por: Fritz, Bradley A., et al.
Publicado: (2022)

Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19
por: Seftel, David, et al.
Publicado: (2021)

Incentivizing an exodus: The implications of recruiting nurses from low-middle income countries to high-income countries
por: Bortolussi-Courval, Émilie, et al.
Publicado: (2023)

MedSafer to Support Deprescribing for Residents of Long-Term Care: a Mixed-Methods Study
por: Perri, Giulia-Anna, et al.
Publicado: (2022)

Fluvoxamine for outpatients with COVID-19: where do we stand?
por: Berwanger, Otavio
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

699. Clinical Outcomes and Management of NAAT-Positive/Toxin-Negative Clostridium difficile Infection: A Systematic Review and Meta-Analysis
por: Prosty, Connor, et al.
Publicado: (2023)

Outpatient treatment of Covid-19 with metformin, ivermectin, and fluvoxamine and the development of Long Covid over 10-month follow-up
por: Bramante, Carolyn T., et al.
Publicado: (2022)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Fluvoxamine in the treatment of anxiety disorders
por: Irons, Jane
Publicado: (2005)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
por: Mills, Fergal P., et al.
Publicado: (2023)

Impact of fluvoxamine on outpatient treatment of COVID-19 in Honduras in a prospective observational real-world study
por: Pineda, Estela, et al.
Publicado: (2022)

The MedSafer Study—Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial
por: McDonald, Emily G., et al.
Publicado: (2022)

Effectiveness of fluvoxamine at preventing COVID-19 infection from turning severe
por: Boretti, Alberto
Publicado: (2023)

Tolerability and safety of fluvoxamine and other antidepressants
por: Westenberg, HGM, et al.
Publicado: (2006)

Fluvoxamine alleviates paclitaxel-induced neurotoxicity
por: Tanimukai, Hitoshi, et al.
Publicado: (2015)

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
por: Reis, Gilmar, et al.
Publicado: (2022)

Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis
por: Liu, Xue, et al.
Publicado: (2018)

Association of a Perioperative Multicomponent Fall Prevention Intervention With Falls and Quality of Life After Elective Inpatient Surgical Procedures
por: Fritz, Bradley A., et al.
Publicado: (2022)

SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids
por: Izumi, Yukitoshi, et al.
Publicado: (2023)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Fluvoxamine for the Early Treatment of COVID-19: A Meta-analysis of Randomized Clinical Trials
por: Guo, Christina M., et al.
Publicado: (2022)

Effect of Text Messaging on Bowel Preparation and Appointment Attendance for Outpatient Colonoscopy: A Randomized Clinical Trial
por: Mahmud, Nadim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7i4ri18q8be6gdla9o4fgbgp7g